About mk2 Biotechnologies
mk2 Biotechnologies is a company based in Munchen (Germany) founded in 2017 by Marco Giuman and Sebastian Mangold. mk2 Biotechnologies operates in a competitive market with competitors including Encodia, Tierra Biosciences, Amide Technologies, Kesmalea and Aquagene, among others.
- Headquarter Munchen, Germany
- Founders Marco Giuman, Sebastian Mangold
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mk2 Biotechnologies Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
SeedBlink
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of mk2 Biotechnologies
Unlock access to complete
Leadership Team
2 people
Product Management Team
2 people
Science Team
1 people
Head Team
1 people
Unlock access to complete
Funding Insights of mk2 Biotechnologies
Investors in mk2 Biotechnologies
mk2 Biotechnologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SeedBlink, Gateway Ventures and OCCIDENT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are provided to deep-tech startups.
|
Locked | Locked | Locked | |
|
An online platform is operated for crowdfunding investments in startups.
|
Locked | Locked | Locked | |
|
Investments in pre-seed and seed-stage startups are facilitated for individuals.
|
Locked | Locked | Locked |
Investor details for mk2 Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by mk2 Biotechnologies
Investment portfolio details for mk2 Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - mk2 Biotechnologies
Detailed financials for mk2 Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mk2 Biotechnologies Comparisons
Peer comparison for mk2 Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of mk2 Biotechnologies
mk2 Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Encodia, Tierra Biosciences, Amide Technologies, Kesmalea and Aquagene, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Technology platforms for integrative proteomic analysis are developed.
|
|
| Locked | Locked | Locked |
AI-based tools for protein development and custom synthesis are offered.
|
|
| Locked | Locked | Locked |
Automated peptide synthesis platform is developed with precision reagents.
|
|
| Locked | Locked | Locked |
Protein homeostasis modulators are developed for therapeutic applications.
|
|
| Locked | Locked | Locked |
Produces high-quality recombinant proteins for research and industrial applications.
|
Detailed competitors of mk2 Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mk2 Biotechnologies
Complete news archive for mk2 Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about mk2 Biotechnologies
mk2 Biotechnologies was founded in 2017 and raised its 1st funding round 4 years after it was founded.
mk2 Biotechnologies is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Konstantinos Antonopoulos is the current CEO of mk2 Biotechnologies.
mk2 Biotechnologies was founded in 2017 in Munich, Germany, within the biotechnology sector. A scalable technology for peptide and protein synthesis is utilized, relying on recombinant methods to support production across various chain lengths. Services are provided to clients in research, development, agriculture, and stock breeding, facilitating applications in these fields. Operations focus on enabling large-scale manufacturing for life science needs.
mk2 Biotechnologies's top competitors include Encodia, Tierra Biosciences and Amide Technologies.
mk2 Biotechnologies has 3 investors. Key investors include SeedBlink, Gateway Ventures, and OCCIDENT.